Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder

2015 ◽  
Vol 24 (3) ◽  
pp. 223-231 ◽  
Author(s):  
Susan L. McElroy ◽  
James E. Mitchell ◽  
Denise Wilfley ◽  
Maria Gasior ◽  
M. Celeste Ferreira-Cornwell ◽  
...  
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Eating Behaviour ◽  
Obsessive Compulsive ◽  
Lisdexamfetamine Dimesylate

scholarly journals Orthorexia Nervosa: differences between clinical and non-clinical samples

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
C. Novara ◽  
E. Maggio ◽  
S. Piasentin ◽  
S. Pardini ◽  
S. Mattioli
Keyword(s):  
Eating Disorders ◽  
Eating Disorder ◽  
Bulimia Nervosa ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Diet Group ◽  
Orthorexia Nervosa ◽  
Clinical Samples ◽  
Control Group ◽  
Obsessive Compulsive

Abstract Background Orthorexia Nervosa (ON) is a construct characterized by behaviors, emotions, and beliefs on eating healthy food and excessive attention to diet; moreover, dieting has been considered a risk factor in ON symptoms development. The principal aim of this study was to investigate the differences in clinical and non-clinical groups most at risk of ON. Aspects that could be associated with ON (Eating Disorders [EDs], obsessive-compulsive symptomatology, perfectionistic traits, anxiety, depression, Body Mass Index [BMI]) were investigated in all groups. Methods The sample consisted of 329 adults belonging to four different groups. Three were on a diet: Anorexia/Bulimia Nervosa group (N = 90), Obesity/Binge Eating Disorder group (N = 54), Diet group (N = 91). The Control group consisted of people who were not following a diet (N = 94). Participants completed several self-administered questionnaires (EHQ-21, EDI-3, OCI-R, MPS, BAI, BDI-II) to assess ON-related features in different groups. Results Analyses highlighted higher orthorexic tendencies in Anorexia/Bulimia Nervosa, Obesity/BED, and Diet groups than in the Control group. Moreover, results have shown that in the AN/BN group, eating disorders symptomatology and a lower BMI were related to ON and that in Obesity/Binge Eating Disorder and Diet groups, perfectionism traits are associated with ON. Conclusion Individuals who pursue a diet share some similarities with those who have an eating disorder regarding emotions, behaviors, and problems associated with orthorexic tendencies. Moreover, perfectionistic traits seem to predispose to higher ON tendencies. In general, these results confirm the ON as an aspect of the main eating disorders category.

Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial

2016 ◽  
Vol 31 (5) ◽  
pp. 382-391 ◽  
Author(s):  
Anna I. Guerdjikova ◽  
Nicole Mori ◽  
Thomas J. Blom ◽  
Paul E. Keck ◽  
Stephanie L. Williams ◽  
...  
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Controlled Trial ◽  
Lisdexamfetamine Dimesylate

scholarly journals The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA

2016 ◽  
Vol 36 (4) ◽  
pp. 305-312 ◽  
Author(s):  
Tamás Ágh ◽  
Manjiri Pawaskar ◽  
Balázs Nagy ◽  
Jean Lachaine ◽  
Zoltán Vokó
Keyword(s):  
Eating Disorder ◽  
Cost Effectiveness ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Lisdexamfetamine Dimesylate ◽  
The Usa ◽  
The Cost

scholarly journals A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder

2017 ◽  
Vol 37 (3) ◽  
pp. 315-322 ◽  
Author(s):  
Maria Gasior ◽  
James Hudson ◽  
Javier Quintero ◽  
M. Celeste Ferreira-Cornwell ◽  
Jana Radewonuk ◽  
...  
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Open Label ◽  
Phase 3 ◽  
Lisdexamfetamine Dimesylate

Eating behaviour, eating disorder and obesity

2000 ◽  
Vol 57 (8) ◽  
pp. 504-510 ◽  
Author(s):  
Zipfel ◽  
Löwe ◽  
Herzog
Keyword(s):  
Eating Disorder ◽  
Bulimia Nervosa ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Eating Behaviour ◽  
Diagnostische Kriterien ◽  
Affektive Störungen ◽  
Therapeutische Optionen ◽  
Dsm Iv

Die Ernährungs- und Bewegungssituation sowie die sozioökonomischen Umstände haben sich in den vergangenen 50 Jahren in den entwickelten Ländern radikal gewandelt. Folgen dieser Entwicklung sind rasante Steigerungen der Prävalenzraten, insbesondere der Adipositas. Kontrastierend hierzu wird weiterhin ein ausgeprägtes Schlankheitsideal propagiert. Dieses Spannungsfeld ist mitverantwortlich für eine steigende Inzidenz von Essstörungen. Hierzu gehören im Gewichtsspektrum des Normal- bis Übergewichtes die Bulimia nervosa und die Esssucht, bisher noch mit dem englischen Begriff der «Binge-Eating-Disorder» bezeichnet. Obwohl die Bulimia Nervosa bereits 1980 in die DSM-III Kriterien aufgenommen wurde, ergaben Untersuchungen, dass bislang nur etwa 12 Prozent der Betroffenen von den Hausärzten entdeckt und richtig diagnostiziert werden. Ein Grund dieser erschreckend niedrigen Zahl liegt in der Dynamik der Erkrankung, mit einer ausgeprägten Tendenz der Patientinnen zur Verheimlichung, ein weiterer Grund mag in einer noch unzureichenden Aufklärung der Hausärzte liegen. Deshalb werden diagnostische Kriterien und therapeutische Optionen dargestellt. Essstörungen im Bereich des Übergewichtes werden seit dem DSM-IV (1994) im Wesentlichen unter dem Begriff der «Binge-Eating-Disorder (BED)» zusammengefasst. 20–30% der adipösen Patienten, die sich in Gewichtsreduktionsprogrammen befinden, leiden unter dieser Essstörung. Erste Untersuchungsergebnisse zeigen, dass diese Subgruppe der Adipösen eine modifizierte Behandlung mit einer stärkeren Fokussierung auf eine Psychotherapie bedarf. Über die initiale Abklärung einer möglichen Essstörung hinaus sollten auch affektive Störungen (Depressivität und Ängstlichkeit) oder ein gestörtes Körperbild erfasst werden. Falls Hinweise auf eine ausgeprägte Störung in diesen Bereichen vorliegen, sollte Psychotherapie fester Bestandteil eines integrierten Therapiekonzeptes der Adipositas sein.

scholarly journals Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial

CNS Spectrums ◽  
2020 ◽  
pp. 1-10 ◽  
Author(s):  
Carlos M. Grilo ◽  
Susan L. McElroy ◽  
James I. Hudson ◽  
Joyce Tsai ◽  
Bradford Navia ◽  
...  
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Global Improvement ◽  
Compulsive Behaviors ◽  
Dose Study

Abstract Objective. The aim of this fixed-dose study was to evaluate the efficacy and safety of dasotraline in the treatment of patients with binge-eating disorder (BED). Methods. Patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for BED were randomized to 12 weeks of double-blind treatment with fixed doses of dasotraline (4 and 6 mg/d), or placebo. The primary efficacy endpoint was change in number of binge-eating (BE) days per week at week 12. Secondary efficacy endpoints included week 12 change on the BE CGI-Severity Scale (BE-CGI-S) and the Yale-Brown Obsessive–Compulsive Scale Modified for BE (YBOCS-BE). Results. At week 12, treatment with dasotraline was associated with significant improvement in number of BE days per week on the dose of 6 mg/d (N = 162) vs placebo (N = 162; −3.47 vs −2.92; P = .0045), but not 4 mg/d (N = 161; −3.21). Improvement vs placebo was observed for dasotraline 6 and 4 mg/d, respectively, on the BE-CGI-S (effect size [ES]: 0.37 and 0.27) and on the YBOCS-BE total score (ES: 0.43 and 0.29). The most common adverse events on dasotraline were insomnia, dry mouth, headache, decreased appetite, nausea, and anxiety. Changes in blood pressure and pulse were minimal. Conclusion. Treatment with dasotraline 6 mg/d (but not 4 mg/d) was associated with significantly greater reduction in BE days per week. Both doses of dasotraline were generally safe and well-tolerated and resulted in global improvement on the BE-CGI-S, as well as improvement in BE related obsessional thoughts and compulsive behaviors on the YBOCS-BE. These results confirm the findings of a previous flexible dose study.

Sign in / Sign up

Export Citation Format

Share Document